Updates from the 2018 European Lupus Society Meeting focus on the risk infection poses to patients with SLE.
References1. Simard J, Rossides M, Arkema E. Serious infection rates in systemic lupus erythematosus: a Swedish population-based assessment. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.2. Iglesias AL, Pego-Reigosa JM, LÃ³pez-Longo FJ, et al. Bacteremia in systemic lupus erythematosus patients from Relesser Registry: risk factors, clinical and microbiological characteristics and outcomes. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.
Two studies presented at the 11th SLEuro Meeting in Dusseldorf, Germany focus on serious infections and bacteremia in patients with systemic lupus erythematosus (SLE).1,2 Click through the slides for the details and the take-home messages for physicians.
SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology.
Nosocomial bacteremia was responsible in 35.1% of cases; a urinary source (27.2%) was most common.
Systemic inflammatory response syndrome developed in 64% of patients, 35% needed intensive care unit admission, and 22.8% had multi-organ failure.
Staphylococcus aureus (16.7% with 22% being methicillin-resistant) and Salmonella species (10.5%) were identified. Of the gram-negative enteric bacilli, 16% were extended-spectrum Ã-lactamase positive, and 17.5% were multidrug resistant.
About 68% of patients started antibiotic therapy before blood culture results were available, which led to susceptibility testing in 56 (71.8%). This testing indicated appropriate antibiotic therapy in 49%.